According to the International Prognostic Scoring System (IPSS) classification [14], plasma galectin-9 levels in AL-MDS patients were markedly higher than in low-risk MDS (IPSS low/intermediate-1) patients (P = 0.0006), but there was no significant difference in the level between low-risk and high-risk MDS (IPSS intermediate-2/high) patients (Figure 5C). The gene discussed is LGALS9; the disease is myelodysplastic syndrome.